Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Neuronostics logo — Revolutionising diagnosis and prognosis of neurological cond...

Neuronostics

Revolutionising diagnosis and prognosis of neurological conditions

Founded 2018 United Kingdom Bristol, United Kingdom 16 employees Seed Total: $4.51M Medical Devices

General Information

Company Name Neuronostics
Founded Year 2018
Location United Kingdom Bristol, United Kingdom
Employees 16
Industries Medical Devices
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with Neuronostics. To contact Neuronostics, visit neuronostics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Neuronostics compare?

A PDF of Neuronostics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Neuronostics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Neuronostics

Neuronostics, founded in 2018 and headquartered in the United Kingdom, is revolutionizing the diagnosis and prognosis of neurological conditions. The company's slogan, "Revolutionising diagnosis and prognosis of neurological conditions," encapsulates their mission. Neuronostics utilizes mathematical modeling to develop novel biomarkers, creating faster paths to diagnosis and effective treatment. With BioEP as their first clinical indication, they have introduced a digital biomarker for epilepsy, which utilizes background EEG data and mathematical modeling to predict the likelihood of seizures. This innovation supports clinical diagnostic and prognostic decisions for epilepsy. The recent £2.10M Seed Round investment on 05 April 2024, with contributions from QantX, Cornwall & Isles of Scilly Investment Fund, Empirical Ventures, and Ascension Life Fund, signifies confidence in Neuronostics' potential to transform neurological healthcare and improve the lives of individuals at risk of or living with neurological conditions. The company's vision of integrating digital biomarkers into neurology centers worldwide is poised to create a proactive and anticipatory model of care, ultimately revolutionizing neurological healthcare.

Business keywords: Neuroscience, Diagnostic tools, Prognostic tools, Pharmaceutical, EEG, Hardware, Partnership, Technology integration, Medical devices, Research and development, Neurological disorders

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round £2.10M 4
QantX Cornwall & Isles of Scilly Investment Fund
QantX, Cornwall & Isles of Scilly Investment Fund +2
05 Apr 2024
Seed Round £500.00K 1
The FSE Group
The FSE Group
04 Oct 2023
Seed Round £300.00K 1
QantX
QantX
26 Mar 2021
Grant £870.00K 1
National Institute for Health Research
08 Sep 2020
Grant £181.55K 1
Innovate UK
Innovate UK
01 Jun 2020
Grant £50.00K 1
Innovate UK
Innovate UK
20 May 2020
Grant £503.85K 1
Innovate UK
Innovate UK
01 Sep 2018

Neuronostics Alternatives & Competitors

View All Alternatives
Neuronostics vs
Neurobit Technologies
Neurobit Technologies Taiwan

We design and manufacture comprehensive neuro-otological diagnostic system for better patient care.

Seed
9 employees
Digital Health, Health Care
Neuronostics vs
NEUROSPEC AG
NEUROSPEC AG Switzerland

Bringing you World-Leading Solutions for Research in Neurosciences

4 employees
Health Care, Medical Devices
Neuronostics vs
Exsurgo
Exsurgo New Zealand

Drug free pain management.

Non Equity Assistance
14 employees
Health Care, Medical Devices
View all alternatives

FAQ About Neuronostics

Revolutionising diagnosis and prognosis of neurological conditions
Neuronostics was founded in 2018.
Neuronostics is headquartered in Bristol, United Kingdom.
Neuronostics operates in Medical Devices. Its work centres on Neuroscience, Diagnostic tools, Prognostic tools and Pharmaceutical.
Neuronostics has approximately 16 employees.
Neuronostics has completed 7 funding rounds, raising a total of $4.51M. The latest funding stage is Seed.
Top alternatives and competitors to Neuronostics include Neurobit Technologies, NEUROSPEC AG, Exsurgo, NeuroVigil, Inc., CorTec. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Neuronostics and Neurobit Technologies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Neuronostics, https://bouncewatch.com/company/neuronostics, updated 29 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout